When Brian Wolpin, Professor of Medicine at Harvard Medical School and Director of the Hale Family Center for Pancreatic Cancer Research at Dana-Farber Cancer Institute, advanced to the next slide during the plenary session at the 2026 ASCO (American Society of...
Akeso and Summit Therapeutics’ ivonescimab plus chemotherapy delivers a statistically significant overall survival benefit over a PD-1 inhibitor plus chemotherapy control in the Phase 3 HARMONi-6 trial for previously untreated advanced squamous non-small cell lung...
The 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, held from 29 May to 2 June in Chicago, drew more than 44,000 oncology professionals and delivered what many clinicians described as some of the most consequential trial data seen at the conference...
Landmark clinical trial results expected in 2026 as disease-modifying Parkinson’s pipeline reaches critical phase Medical research charity Cure Parkinson’s says the Parkinson’s research field is approaching a pivotal moment, as a wave of results from clinical trials...
Apogee Therapeutics’ zumilokibart meets its primary and all secondary endpoints with high statistical significance in the Phase 2 APEX Part B trial for moderate-to-severe atopic dermatitis, TG Therapeutics’ BRIUMVI receives positive Phase 3 ENHANCE data supporting a...
There’s a lot of discussion right now around AI in healthcare, but most of it feels disconnected from how clinical research actually works day-to-day. A lot of the conversation is centered around automation, replacing people, chatbots, and efficiency. Some of that...
Amgen’s subcutaneous reformulation of Tepezza meets its Phase 3 primary endpoint in thyroid eye disease, Lipocine’s oral brexanolone suffers a significant Phase 3 setback in postpartum depression, and NervGen Pharma secures FDA alignment on the RESTORE Phase 3...
The Growing Strain on Clinical Trial Operations Clinical trials have become increasingly diverse, complex, and expensive over the past decade. As the industry moves toward a more globalized model, managing timelines, coordinating across clinical functions, and...
Beam Therapeutics' base edited cell therapy for sickle cell disease earns a landmark NEJM publication, Immunovant's batoclimab misses in two Phase 3 thyroid eye disease trials, Seaport Therapeutics unlocks a novel anxiety treatment pathway, and Eli Lilly's oral GLP-1...
International Menopause Society sets new global standards for menopause care with evidence-led framework For the first time in a decade, the International Menopause Society (IMS) has released a complete redevelopment of its global menopause recommendations. Grounded...
An RNA therapy that preserves muscle while cutting visceral fat, a first in class oral non incretin obesity pill, late stage lung cancer portfolio data, NK cell immunotherapy in Alzheimer’s disease, and the first human trial of a cellular rejuvenation medicine...
This week brought a remarkable series of clinical trial readouts spanning oncology, metabolic disease, neurology, and dermatology. Several pivotal datasets were released from late-stage and early-stage programmes, offering fresh hope for patients with conditions...
We work with hospitals, clinics, and health systems across the country every day. Over the past few years, one thing has become very clear: filling a specialist role is harder than it used to be, it takes longer, and the consequences of getting it wrong reach further...
Drug development is one of the most expensive and time-intensive innovation processes in the world. Estimates from the Tufts Center for the Study of Drug Development suggest that bringing a new drug to market can cost over $2.6 billion and take more than a decade of...
Medication non-adherence and dropout have long been labeled “known problems” in the clinical trial space. Yet despite years of tinkering with the formula, these challenges have only become “well-known problems.” Operational efficiencies and innovation, digital...
At the 2026 Congress of the European Society of Gynaecological Oncology (ESGO) in Copenhagen, Dr Gabriel Levin of the McGill University Health Centre will present Phase II data evaluating the investigational DNA therapy Elenagen in combination with gemcitabine for...
Dr Steven Cox, CEO of the research charity, Cardiac Risk in the Young (CRY) explains the key findings and importance of a seminal study (reviewing cardiac screening data collated over a 10 year period), published on 24 February 2026 in the Journal of the American...
Couples trying to conceive are bombarded with supplement recommendations. Scroll through any fertility forum and you'll find confident claims about CoQ10, vitamin D, and a dozen other compounds that supposedly hold the key to conception. Some of these recommendations...